The Liver Meeting 2020-COVID-19 and the Liver Clinical Symposium

Video Transcription

Video Summary

The symposium "COVID-19 in the liver" discussed the impact of COVID-19 on clinical practices and patient care. Topics included diagnosis, treatment, outcomes, and hepatic manifestations of COVID-19. Speakers highlighted liver enzyme elevation in patients, indicating potential liver injury. Studies on dexamethasone and remdesivir showed effectiveness in reducing mortality, especially in advanced cases. Disparities in treatment and outcomes among Black, Latinx, and Native American populations were noted due to socioeconomic factors and healthcare access. Factors like age, comorbidities, race, and socioeconomic status play a role in COVID-19 impact. Challenges in healthcare access, food insecurity, and telehealth further compound disparities, requiring a multifaceted approach to improve healthcare access and reduce inequalities. Efforts to address disparities must focus on preventive care and healthcare access for vulnerable populations.

Keywords

COVID-19

liver

clinical practices

patient care

diagnosis

treatment

outcomes

hepatic manifestations

liver enzyme elevation

dexamethasone

remdesivir

mortality reduction

healthcare disparities